General presentation of Novavax
We now offer you the opportunity to learn more about the Novavax Company and its activity sector. In fact, if you wish to fully understand how this company can generate growth or face coming challenges then you will need to be aware of the major sources of revenue for this company and the sectors in which it operates. This is what we shall examine here:
The group Novavax Inc. is also an American company specialised in the development of vaccines. This company develops vaccines at a clinical stage by concentrating on the discovery and development as well as the manufacture and sale of vaccines and adjuvants through recombined nanoparticles. This company also exercises activities in the sector of recombined vaccines.
The nanoparticle recombination technology is in fact a specialty of this group that produces vaccine candidates with the aim of responding to known or new emerging illnesses and diseases.
Concerning the product portfolio developed and marketed by this company, this mainly relates to a range of infectious diseases with vaccine candidates that are being clinically developed for Covid-19, the RSV respiratory syncytial virus, seasonal flu, pandemic flu and also the Ebola and EBOV viruses. The group is in fact currently undertaking phase II and III clinical trials for a vaccine candidate against the H7N7 pandemic using its principal adjuvant Matrix-M which is currently being tested as well as its EBOV vaccine candidate under phase I clinical trials. Novavax is also developing other pre-clinical programmes at present for a range of infectious diseases including the Middle East respiratory syndrome.
The Novavax Company currently employs over 160 people in the United States.
67% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro